Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Donna Tempel
AddedMar 31, 2024
UpdatedMay 31, 2026
Donna Tempel

Donna Tempel

CEO, Telsar Pharma

CrunchbaseLinkedIn

Donna Tempel's Career

Telsar Pharma
Telsar Pharma

Bridgewater Township, NJ, US

CEO· C-Suite · Management
Drais Pharmaceuticals
Drais Pharmaceuticals

Bridgewater Township, NJ, US

Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Donna Tempel's Career

Telsar Pharma
Telsar Pharma
Series A$14M52012Bridgewater Township, NJ, US
CEO· C-Suite · Management

Similar to Telsar Pharma

Tarsus PharmaceuticalsTarsus PharmaceuticalsIrvine, CA, USTherapeuticsest. 2017Tarsus PharmaceuticalsIrvine, CA, US · est. 2017

Tarsus: A private, clinical-stage biopharmaceutical firm based in Irvine, California.

Public · $410.6M251
White Sands PharmaWhite Sands PharmaLittle Rock, AR, USPharmaceuticalsest. 2014White Sands PharmaLittle Rock, AR, US · est. 2014

Innovative pharma company developing novel IBS treatments.

Seed · $4.3M6
Sarkana PharmaSarkana PharmaWilmington, DE, USPharmaceuticalsest. 2020Sarkana PharmaWilmington, DE, US · est. 2020

Delaware-based pharma developing anti-inflammatory biologics for autoimmune diseases.

Seed · $1.6M6
Transparency Life SciencesTransparency Life SciencesNew York City, NY, USDrug Developmentest. 2012Transparency Life SciencesNew York City, NY, US · est. 2012

TLS: A leading US-based Aino tech provider, innovating in drug development for diverse diseases.

Series A · $5M10
Drais Pharmaceuticals
Drais Pharmaceuticals
$33M112007Bridgewater Township, NJ, US
Founder & CEO· C-Suite · Management

Leadership at Drais Pharmaceuticals

Arnie OronskyArnie OronskyBoard Member
Jeff BirdJeff BirdBoard Member

Similar to Drais Pharmaceuticals

Dracen PharmaceuticalsDracen PharmaceuticalsBaltimore, MD, USCancer Treatmentest. 2016Dracen PharmaceuticalsBaltimore, MD, US · est. 2016

Dracen Pharmaceuticals: Innovating cancer treatment through novel glutamine antagonists.

Seed · $50.9M375
Tigris PharmaceuticalsTigris PharmaceuticalsBonita Springs, FL, USCancer Treatmentsest. 2005Tigris PharmaceuticalsBonita Springs, FL, US · est. 2005

Tigris Pharmaceuticals: Innovating biopharmaceutical solutions for cancer and other medical needs.

Series C · $32.5M6
Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7
OncoTartisOncoTartisBuffalo, NY, USAnti-Cancer Drugsest. 2011OncoTartisBuffalo, NY, US · est. 2011

OncoTartis, Inc.: A private biotech firm innovating targeted anti-cancer drugs for specific malignancies.

Series A · $6M8

People Similar to Donna Tempel

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoDavid StevensDavid StevensFounder · DRS HealthTom EstokTom EstokFounder · Dracen PharmaceuticalsRichard LowenthalRichard LowenthalCo-Founder & CEO · ARS PharmaceuticalsJonathan SacksJonathan SacksCEO · PharmAdvaDon WilsonDon WilsonFounder & CEO · DRWDean DrakoDean DrakoFounder & CEO · Eagle Eye Networks